ArticleMarine biotechnology (New York, N.Y.)2026
Optimal Dietary Isoleucine Promotes Growth, Regulates Lipid Metabolism, and Modulates Hepatopancreatic Microbiota in Juvenile mud crab (Scylla paramamosain).
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study investigated the effects of dietary isoleucine on growth performance, digestive and metabolic enzyme activities, antioxidant capacity, and hepatopancreatic microbiota in juvenile Scylla paramamosain. Five isonitrogenous and isolipidic diets were formulated with graded isoleucine levels: 0.97% (Ile 1), 1.19% (Ile 2), 1.57% (Ile 3), 1.74% (Ile 4), and 2.09% (Ile 5). A total of 560 juveniles (initial weight: 15.07 ± 1.37 mg) were fed for 8 weeks. Results showed that weight gain rate (WGR) and specific growth rate (SGR) significantly increased with dietary isoleucine levels up to 1.57% and declined thereafter. Broken-line regression analysis based on WGR estimated the optimal dietary isoleucine requirement at 1.43%. Hepatopancreatic alanine aminotransferase (ALT) activity was highest in the 1.57% group, whereas trypsin and lipase activities did not differ significantly among treatments. Dietary isoleucine levels influenced lipid metabolism, with excessive supplementation (2.09%) associated with reduced growth and increased whole-body crude lipid content, accompanied by upregulated expression of fas, srebp1, acc and downregulated hsl expression. Appropriate dietary isoleucine levels (1.19%-1.57%) increased hepatopancreatic superoxide dismutase (SOD) activity and reduced malondialdehyde (MDA) content. Hepatopancreatic microbial α-diversity and overall community structure did not differ significantly among treatments, although Thiothrix showed the highest relative abundance in the 1.57% group. PICRUSt2 analysis suggested differences in predicted microbial metabolic functions among treatments. Overall, the estimated dietary isoleucine requirement for juvenile S. paramamosain was 1.43%, while excessive dietary isoleucine impaired growth and was associated with increased lipid deposition.
Indexed as
Identifiers
42905188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.